Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 02:15PM GMT
David Neil Lebowitz - Morgan Stanley, Research Division - VP

Welcome once again to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we get started, let me jump into the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'm happy to introduce in the next session from Arcutis, CEO, Frank Watanabe; CFO, Scott Burrows; CCO, Ken Lock; and CMO, Patrick Burnett.

Questions and Answers:

David Neil Lebowitz - Morgan Stanley, Research Division - VP

I guess if you could start out Arcutis is late-stage dermatology company. You have one drug that already produced Phase III results and other -- some other Phase III trials that are in the works. Could you talk about the top level vision
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot